Investment funds target Valeant’s iNova (AUD1bn)

US investment fund KKR seems to be targeting Australia-based iNova, owned by Valeant group, The Australian Financial Review reports. KKR, indeed, is allegedly about to initiate acquiring iNova, valued at least AUD1bn. The newspaper also mentions Pacific Equity Partners and GlaxoSmithKline as potential bidders, even though the latter is reportedly considering only a part of the company’s assets.
(Source Australian Financial Review)